AE1/AE3

Last updated
Histopathology of a pelvic lymph node in a patient with endometrial adenocarcinoma (FIGO grade 1): - Left panel shows H&E staining and low magnification, where any presence of small metastases is hard to see. - Middle panel shows immunohistochemistry for CK AE1/AE3, which highlights even small tumor nests. - The right panel shows high magnification on a positive area, confirming adenocarcinoma, as it shows tumor cells with large nuclei and prominent nucleoli. HE histopathology and CK AE1-AE3 immunohistochemistry in endometrial adenocarcinoma metastasis to lymph node.png
Histopathology of a pelvic lymph node in a patient with endometrial adenocarcinoma (FIGO grade 1):
- Left panel shows H&E staining and low magnification, where any presence of small metastases is hard to see.
- Middle panel shows immunohistochemistry for CK AE1/AE3, which highlights even small tumor nests.
- The right panel shows high magnification on a positive area, confirming adenocarcinoma, as it shows tumor cells with large nuclei and prominent nucleoli.

AE1/AE3 is an antibody cocktail that is used in immunohistochemistry, being generally positive in the cytoplasm of carcinomas (cancers of epithelial origin). [1] [2]

Contents

Targets

The antibody cocktail binds to cytokeratin 1 - 8, 10, 14 - 16 and 19 (but not CK17 or CK18). [1] It is therefore used as a marker of carcinomas, such as depth of invasion and metastases. [1] For example, it is both relatively sensitive and specific for detection of breast cancer metastasis to sentinel lymph nodes. [3]

It may cross-react with GFAP, leading to aberrant staining of glial tumors such as ependymoma, glioblastoma and schwannoma. [1] It may also stain myofibroblasts and smooth muscle cells. [1] Furthermore, it may stain nodal epithelial cells that has contaminated a tumor from recent biopsy. [1]

See also

References

  1. 1 2 3 4 5 6 "Stains - Cytokeratin AE1 / AE3". PathologyOutlines. 2013-07-01. Revised: 26 November 2019
  2. ↑ Cytoplasmic stain: "Pan Cytokeratin [AE1/AE3]". BioCare Medical. Retrieved 2021-05-12.
  3. ↑ Xu X, Roberts SA, Pasha TL, Zhang PJ (2000). "Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma". Arch Pathol Lab Med. 124 (9): 1310–3. doi:10.5858/2000-124-1310-UCIONN. PMID   10975928.{{cite journal}}: CS1 maint: multiple names: authors list (link)


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.